Effect of Evodia rutaecarpa plus oseltamivir in regulating body temperature and inflammatory cytokines in infants and young children with viral fever
Pakistan Journal of Pharmaceutical Sciences · 01.02.2027
DOI: 10.36721/pjps/2026.40.15800.1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pakistan Journal of Pharmaceutical Sciences, online erschienen am 08.10.2026. Verfasst von Tiantuo Peng. Die Arbeit nennt 24 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background: viral fever is a common acute infectious disease among infants and young children. Oseltamivir, a first-line antiviral drug, has limitations in inflammation regulation. In contrast, Evodia Rutaecarpa (E. Rutaecarpa) has been proven to exert antipyretic effects in traditional Chinese medicine.
Objectives
This study, for the first time, systematically evaluated the efficacy of topical E. Rutaecarpa acupoint preparation plus Oseltamivir in treating viral fever in infants and young children.
Methods
In this retrospective analysis, we included 60 pediatric cases between the ages of 6 months and 3 years and assigned them 1:1 according to propensity score matching (PSM): a combined group (topical E. Rutaecarpa acupoint application + oral Oseltamivir) and a control group (oral Oseltamivir alone). The treatment course lasted for 5 days. The main outcome measure was antipyretic time and the secondary outcome measures included changes in body temperature at different time points, serum inflammatory factors (tumor necrosis factor-α [TNF-α] and interleukin-6 [IL-6], interleukin-1β [IL-1β], high-sensitivity C-reactive protein [hs-CRP]) levels, treatment comfort score (TCS), sleep quality index (SQI), adverse reactions and parents' satisfaction.
Results
The antipyretic time was found to be shorter in the combined group than in the control group. Besides, the combined therapy led to markedly milder body temperature fluctuations at 24 hours and 48 hours, as well as greater decreases in serum inflammatory markers (tumor necrosis factor-α [TNF-α] and interleukin-6 [IL-6]), compared to Oseltamivir monotherapy. Additionally, improved TCS and PSQI scores were found in pediatric patients receiving E. Rutaecarpa + Oseltamivir, together with superior parental satisfaction (P
Zitieren
APA
Peng, T. (2027). Effect of Evodia rutaecarpa plus oseltamivir in regulating body temperature and inflammatory cytokines in infants and young children with viral fever. Pakistan Journal of Pharmaceutical Sciences. https://doi.org/10.36721/pjps/2026.40.15800.1
Vancouver
Peng T. Effect of Evodia rutaecarpa plus oseltamivir in regulating body temperature and inflammatory cytokines in infants and young children with viral fever. Pakistan Journal of Pharmaceutical Sciences. 2027. doi:10.36721/pjps/2026.40.15800.1
BibTeX
@article{Peng2027,
author = {Peng, Tiantuo},
title = {Effect of Evodia rutaecarpa plus oseltamivir in regulating body temperature and inflammatory cytokines in infants and young children with viral fever},
journal = {Pakistan Journal of Pharmaceutical Sciences},
year = {2027},
doi = {10.36721/pjps/2026.40.15800.1}
}
EUVIMED